Back to Search Start Over

Lymphoepithelioma-like hepatocellular carcinoma

Authors :
Yan-Wen Jin
Fu-Yu Li
Hai-Jie Hu
Jun-Ke Wang
Parbatraj Regmi
Qin Yang
Cong-Dun Ran
Er-Liang Zheng
Fei Su
Fei Liu
Wen-Jie Ma
Source :
Medicine. 96:e9416
Publication Year :
2017
Publisher :
Ovid Technologies (Wolters Kluwer Health), 2017.

Abstract

We report a case of hepatic lymphoepithelioma-like carcinoma-hepatocellular carcinoma subtype (LEL-HCC) in a 41-year-old man with chronic hepatitis C virus (HCV) infection. The patient presented with abdominal pain and further assessment revealed a hypoechoic mass on ultrasonography. Serum alpha-fetoprotein (AFP) was 13·6 ng/dl. The patient was diagnosed as hepatocellular carcinoma based on the established triphasic computed tomography (TCT) diagnostic criteria and he underwent a surgical resection of the mass. Microscopic examination showed sheets and cords of malignant epithelial cells intermixed with heavy lymphoid infiltrate, with more than 100 tumor-infiltrating lymphocytes (TILs) per 10 high-power-field (HPF). Based on immunohistochemical studies, the malignant cells were positive for Hep Par 1 and glypican 3, focally positive for cytokeratin 7 (CK7), and negative for cytokeratin 20 (CK20). TILs were diffusely positive for cluster of differentiation 3 CD3 with an approximately equal CD4/CD8 ratio. The patient was recurrence free at 25 months after surgery, as evident by CT and serum alpha-fetoprotein level. LEL-HCC is a rare variant of HCC with a relatively better prognosis. Exploring the potential for immune modulator-based therapy in this subset of tumors is highly recommended.

Details

ISSN :
00257974
Volume :
96
Database :
OpenAIRE
Journal :
Medicine
Accession number :
edsair.doi.dedup.....1a7afe939f7b60f61a7078cc22e7969d
Full Text :
https://doi.org/10.1097/md.0000000000009416